On 16 June 2021, a summary of the results obtained in the phase 1 and phase 2 of the clinical trials have been published in the press.[41][42] According to the report, only mild adverse effects were registered execept one case of hypotension, one case of level-2 headache and one case of diminution of platelets that didn't need medical care.[3] Conventionnal Virus Neutralizing Test (cVNT) is reported to have shown 93.5% immunogenicity (95% confidence interval: 88.4 – 99.6%).[6] On 23 June 2021, the production project manager of the vaccine stated that the results of the second phase have shown "the serum of the people who received the vaccine has 93.5% power to neutralize the virus; thus meaning the vaccine has a very good efficacy that will be shown after the end of the third phase".[43]